Trials / Unknown
UnknownNCT04190823
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC98 For Injection in Subjects With Advanced Malignant Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability and pharmacokinetics of RC98 for injeciton in subjects with advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC98 | Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period. |
Timeline
- Start date
- 2020-03-15
- Primary completion
- 2023-12-28
- Completion
- 2023-12-30
- First posted
- 2019-12-09
- Last updated
- 2023-11-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04190823. Inclusion in this directory is not an endorsement.